IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v42y2019i5d10.1007_s40264-018-0782-8.html
   My bibliography  Save this article

Managing Risks with Immune Therapies in Multiple Sclerosis

Author

Listed:
  • Moritz Förster

    (Heinrich-Heine-University)

  • Patrick Küry

    (Heinrich-Heine-University)

  • Orhan Aktas

    (Heinrich-Heine-University)

  • Clemens Warnke

    (University Hospital Cologne)

  • Joachim Havla

    (Ludwig-Maximilian-Universität München)

  • Reinhard Hohlfeld

    (Ludwig-Maximilian-Universität München
    The Munich Cluster for Systems Neurology (SyNergy))

  • Jan Mares

    (University Hospital and Faculty of Medicine and Dentistry, Palacky University)

  • Hans-Peter Hartung

    (Heinrich-Heine-University)

  • David Kremer

    (Heinrich-Heine-University)

Abstract

Since the introduction of the interferons in the 1990s, a multitude of different immunomodulatory and immunosuppressant disease-modifying therapies for multiple sclerosis (MS) have been developed. They have all shown positive effects on clinical endpoints such as relapse rate and disease progression and are a heterogeneous group of therapeutics comprising recombinant pegylated and non-pegylated interferon-β variants, peptide combinations, monoclonal antibodies, and small molecules. However, they have relevant side effect profiles, which necessitate thorough monitoring and straightforward patient education. In individual cases, side effects can be severe and potentially life-threatening, which is why knowledge about (neurological and non-neurological) adverse drug reactions is essential for prescribing neurologists as well as general practitioners. This paper aims to provide an overview of currently available MS therapies, their modes of action and safety profiles, and the necessary therapy monitoring.

Suggested Citation

  • Moritz Förster & Patrick Küry & Orhan Aktas & Clemens Warnke & Joachim Havla & Reinhard Hohlfeld & Jan Mares & Hans-Peter Hartung & David Kremer, 2019. "Managing Risks with Immune Therapies in Multiple Sclerosis," Drug Safety, Springer, vol. 42(5), pages 633-647, May.
    • Handle: RePEc:spr:drugsa:v:42:y:2019:i:5:d:10.1007_s40264-018-0782-8
    DOI: 10.1007/s40264-018-0782-8
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-018-0782-8
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-018-0782-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:42:y:2019:i:5:d:10.1007_s40264-018-0782-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.